Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of a New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Author's Avatar
Apr 07, 2022

Company to Host Webcast Wednesday, April 13, 2022 at 11am ET